<SEC-DOCUMENT>0001437749-24-030300.txt : 20241001
<SEC-HEADER>0001437749-24-030300.hdr.sgml : 20241001
<ACCEPTANCE-DATETIME>20241001080306
ACCESSION NUMBER:		0001437749-24-030300
CONFORMED SUBMISSION TYPE:	424B3
PUBLIC DOCUMENT COUNT:		4
FILED AS OF DATE:		20241001
DATE AS OF CHANGE:		20241001

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CervoMed Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B3
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-279343
		FILM NUMBER:		241341373

	BUSINESS ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116
		BUSINESS PHONE:		(617) 744-4400

	MAIL ADDRESS:	
		STREET 1:		20 PARK PLAZA
		STREET 2:		SUITE 424
		CITY:			BOSTON
		STATE:			MA
		ZIP:			02116

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Diffusion Pharmaceuticals Inc.
		DATE OF NAME CHANGE:	20160115

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B3
<SEQUENCE>1
<FILENAME>crvo20240930_424b3.htm
<DESCRIPTION>FORM 424B3
<TEXT>
<html><head>
	<title>crvo20240930_424b3.htm</title>

	<!-- Generated by ThunderDome Portal - 9/30/2024 9:48:47 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<div contenteditable="false" docsect="1" id="567392" sectdesc="Section">&nbsp;</div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Filed pursuant to Rule 424(b)(3)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Registration No.: 333-279343</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>PROSPECTUS SUPPLEMENT No. 5</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>(to the Prospectus dated June 5, 2024, as supplemented by </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Prospectus Supplement No. 1, dated June 14, 2024, </b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Prospectus Supplement No. 2, dated July 12, 2024,</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Prospectus Supplement No. 3, dated August 1, 2024, and</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Prospectus Supplement No. 4, dated August 9, 2024)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="text-align:center;font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"><img alt="crvo20240930_424b3img001.jpg" src="crvo20240930_424b3img001.jpg" style="width:411;height:127;"></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:36pt;"><b>5,064,570 Shares of Common Stock</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This prospectus supplement No. 5 (the &#8220;Prospectus Supplement&#8221;) amends and supplements our prospectus contained in our Registration Statement on Form S-1, effective as of June 5, 2024, as supplemented by Prospectus Supplement No. 1, dated June 14, 2024, Prospectus Supplement No. 2, dated July 12, 2024, Prospectus Supplement No. 3, dated August 1, 2024, and Prospectus Supplement No. 4, dated August 9, 2024 (as supplemented from time to time, the &#8220;Prospectus&#8221;), related to the resale by the selling stockholders identified in the Prospectus of up to an aggregate of 5,064,570 shares of our common stock, par value $0.001 per share (the &#8220;Common Stock&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Prospectus Supplement is being filed in order to incorporate into and include in the Prospectus the information contained in our attached Current Report on Form 8-K, filed with the Securities and Exchange Commission on October 1, 2024.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">This Prospectus Supplement should be read in conjunction with the Prospectus and is qualified by reference to the Prospectus except to the extent that the information in this Prospectus Supplement supersedes the information contained therein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our Common Stock is listed on the NASDAQ Capital Market under the symbol &#8220;CRVO.&#8221; The last reported closing price of our Common Stock on the NASDAQ Capital Market on September 30, 2024, was $14.60.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Investing in our securities involves risks. See </b>&#8220;<b>Risk Factors</b>&#8221;<b> beginning on page 9 of the Prospectus and in the documents incorporated by reference in the Prospectus for a discussion of the factors you should carefully consider before deciding to purchase these securities.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b>Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or determined if this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The date of this Prospectus Supplement is October 1, 2024.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<div contenteditable="false" docsect="1" id="567393" sectdesc="Section">&nbsp;</div>

<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>UNITED STATES</b></p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Washington, D.C. 20549</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:18pt;font-variant:normal;text-align:center;margin:0pt;"><b>FORM 8-K</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CURRENT REPORT</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Pursuant to Section 13 or 15(d)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of The Securities Exchange Act of 1934</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>September 26, 2024</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date of Report (Date of earliest event reported)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed Inc.</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Exact name of registrant as specified in its charter)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Delaware</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>001-37942</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>30-0645032</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(State or other jurisdiction</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>of incorporation)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Commission</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>File Number)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(I.R.S. Employer</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Identification No.)</b></p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td colspan="3" style="vertical-align: middle; width: 66%;">&nbsp;</td>
			<td colspan="1" style="vertical-align: middle; width: 33%;">&nbsp;</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 66%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>20 Park Plaza, Suite 424</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Boston, Massachusetts</b></p>
			</td>
			<td style="vertical-align: bottom; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>02116</b></p>
			</td>
		</tr>
		<tr>
			<td colspan="3" style="vertical-align: top; width: 66%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Address of principal executive offices)</b></p>
			</td>
			<td style="vertical-align: top; width: 33%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Zip Code)</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>s telephone number, including area code: (617) 744-4400</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Not applicable</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>(Former name or former address, if changed since last report)</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<hr style="text-align: center; height: 1px; color: #000000; background-color: #000000; width: 25%; border: none; margin: 3pt auto">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 18pt;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&#9744;</p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Title of each class</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Trading</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Symbol(s)</b></p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name of each exchange</b></p>

			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>on which registered</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Common Stock, $0.001 par value</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">CRVO</p>
			</td>
			<td style="vertical-align: bottom; width: 2%;">&nbsp;</td>
			<td style="vertical-align: top; width: 32%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">NASDAQ Capital Market</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company&nbsp;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&nbsp;&nbsp;&#9744;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0">
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0">
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Item&nbsp;8.01</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Other Events</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">On September 26, 2024, CervoMed Inc. (the &#8220;Company&#8221;) issued a press release announcing that it will deliver two oral presentations that inform on the potential of neflamapimod as a treatment for patients with dementia with Lewy bodies (DLB) at the Clinical Trials on Alzheimer&#8217;s Disease Conference (CTAD) taking place October 29 &#8211; November 1, 2024, in Madrid, Spain. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">

		<tr style="vertical-align: top;">
			<td style="width: 63pt;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Item&nbsp;9.01</b></p>
			</td>
			<td style="width: auto;">
			<p style="margin: 0pt; text-align: left; font-family: 'Times New Roman', Times, serif; font-size: 10pt;"><b>Financial Statements and Exhibits</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><i>(d)</i></b>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b><i>Exhibits</i></b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit No.</b></p>
			</td>
			<td style="vertical-align:bottom;width:3.4%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 85%; border-bottom: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">99.1</p>
			</td>
			<td style="vertical-align:top;width:3.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_728630.htm" style="-sec-extract:exhibit;">Press Release, issued September 26, 2024</a></p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:top;width:11.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">104</p>
			</td>
			<td style="vertical-align:top;width:3.4%;">&nbsp;</td>
			<td style="vertical-align:top;width:85%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cover Page Interactive Data File (embedded within the Inline XBRL document).</p>
			</td>
		</tr>

</table>

<p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNATURES</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="text-indent: 0; width: 100%;font-family: 'Times New Roman', Times, serif; font-size: 10pt">

		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Date: October 1, 2024</p>
			</td>
			<td colspan="2" style="width: 5%;" valign="top" width="38%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><b>CervoMed Inc.</b></p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 5%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td align="left" nowrap="nowrap" style="width: 35%;" valign="bottom" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td align="left" style="text-align: left; width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="text-align: left; width: 5%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">By: </font></p>
			</td>
			<td align="left" nowrap="nowrap" style="border-bottom: 1px solid rgb(0, 0, 0); width: 35%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">/s/&nbsp;</font>William Elder</p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 5%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Name:</p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">William Elder</p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>
		<tr>
			<td style="width: 50%;" valign="top" width="50%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
			<td style="width: 5%;" valign="top" width="3%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Title:</p>
			</td>
			<td style="width: 35%;" valign="top" width="35%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;">Chief Financial Officer &amp; General Counsel</p>
			</td>
			<td style="width: 10%;" valign="top" width="12%">
			<p style="margin: 0px 0pt; font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>
			</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 252pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex_728630.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html><head>
	<title>ex_728559.htm</title>

	<!-- Generated by ThunderDome Portal - 9/30/2024 8:59:53 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin: 0px 0pt; text-align: right; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 99.1</b></font></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font><img alt="logosm.jpg" src="logosm.jpg"></p>

<p style="margin: 0px 0pt; text-align: left; font-size: 10pt; font-family: &quot;Times New Roman&quot;;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CervoMed to Deliver Late-Breaking Oral Presentations at the 17</b><b><sup style="vertical-align:top;line-height:120%;">th</sup></b><b> Clinical Trials on Alzheimer's Disease Conference (CTAD)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><i>Plasma biomarker data from AscenD-LB Phase 2a study and baseline data from the RewinD-LB Phase 2b study to be featured in late-breaking oral presentations at CTAD</i></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Boston, September 26, 2024 </b>&#8211;<b> </b>CervoMed Inc. (NASDAQ: CRVO), a clinical-stage company focused on developing treatments for age-related neurologic disorders, today announced that it will deliver two oral presentations that inform on the potential of neflamapimod as a treatment for patients with dementia with Lewy bodies (DLB) at the Clinical Trials on Alzheimer&#8217;s Disease Conference (CTAD) taking place October 29 &#8211; November 1, 2024, in Madrid, Spain.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#8220;We are delighted that both of our abstracts have been accepted as late-breaking oral presentations at this year&#8217;s CTAD,&#8221; said John Alam, MD, Chief Executive Officer of CervoMed. &#8220;This recognition by the conference scientific committee, whom we thank, reflects both the urgent need to address the impact of DLB on patients and their families and the importance of the ongoing RewinD-LB Phase 2b study to the dementia clinical research community.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dr. Alam continued, &#8220;The baseline data from RewinD-LB demonstrates the disease burden at study entry is consistent with our expectations when we designed and powered the study. Additionally, the plasma biomarker data indicate that neflamapimod acts on the underlying disease process in DLB. Combined, the findings being reported in the two presentations increase our confidence in the RewinD-LB trial&#8217;s positive outcome. We look forward to reporting the topline data from RewinD-LB in December of this year.&#8221;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Details of the CTAD presentations are as follows:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Abstract Title:</b> <i>Plasma biomarker data indicates clinical activity of neflamapimod in dementia with Lewy bodies (DLB) is mediated through effects on the basal forebrain cholinergic system </i><br>
<b>Format: </b>Oral Presentation<br>
<b>Session Name: </b>Late Breaking Oral Communications<br>
<b>Session Date and Time:</b> Friday, November 1, 2024, 11:15 am CET</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Abstract Title:</b><i> Participants enrolled in the RewinD-LB clinical trial: a large cohort of patients with dementia with Lewy bodies (DLB) without tau-related temporal lobe neurodegeneration, as defined by absence of elevation in plasma ptau181</i><br>
<b>Format: </b>Oral Presentation<br>
<b>Session Name: </b>Late Breaking Oral Communications<br>
<b>Session Date and Time: </b>Friday, November 1, 2024, 4:40 pm CET</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"><img alt="logosm.jpg" src="logosm.jpg"></p>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>About CervoMed</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CervoMed Inc. (the &#8220;Company&#8221;) is a clinical-stage company focused on developing treatments for age-related neurologic disorders. The Company is currently developing neflamapimod, an investigational, orally administered small molecule brain penetrant that inhibits p38 mitogen-activated protein kinase alpha. Neflamapimod has the potential to treat synaptic dysfunction, the reversible aspect of the underlying neurodegenerative processes that causes disease in DLB and certain other major neurological disorders. Neflamapimod is currently being evaluated in a Phase 2b study in patients with early-stage DLB.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Forward-Looking Statements</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This press release includes express and implied forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, regarding the intentions, plans, beliefs, expectations or forecasts for the future of the Company, including, but not limited to, the therapeutic potential of neflamapimod and the anticipated timing and achievement of clinical and development milestones, including the completion and achievement of primary endpoints of the RewinD-LB Phase 2b clinical trial and the Company&#8217;s announcement of topline data therefrom. Terms such as &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;anticipates,&#8221; &#8220;expects,&#8221; &#8220;plans,&#8221; &#8220;aims,&#8221; &#8220;seeks,&#8221; &#8220;intends,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;could,&#8221; &#8220;might,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; &#8220;approximately,&#8221; &#8220;potential,&#8221; &#8220;target,&#8221; &#8220;project,&#8221; &#8220;contemplate,&#8221; &#8220;predict,&#8221; &#8220;forecast,&#8221; &#8220;continue,&#8221; or other words that convey uncertainty of future events or outcomes (including the negative of these terms) may identify these forward-looking statements. Although there is believed to be reasonable basis for each forward-looking statement contained herein, forward-looking statements by their nature involve risks and uncertainties, known and unknown, many of which are beyond the Company&#8217;s control and, as a result, actual results could differ materially from those expressed or implied in any forward-looking statement. Particular risks and uncertainties include, among other things, those related to: the Company&#8217;s available cash resources and the availability of additional funds on acceptable terms; the results of the Company&#8217;s clinical trials, including RewinD-LB; the likelihood and timing of any regulatory approval of neflamapimod or the nature of any feedback the Company may receive from the U.S. Food and Drug Administration; the ability to implement business plans, forecasts, and other expectations in the future; general economic, political, business, industry, and market conditions, inflationary pressures, and geopolitical conflicts; and the other factors discussed under the heading &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023 filed with the U.S. Securities and Exchange Commission (SEC) on March 29, 2024, and other filings that the Company may file from time to time with the SEC. Any forward-looking statements in this press release speak only as of the date hereof (or such earlier date as may be identified). The Company does not undertake any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except to the extent required by law.</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Investor Contact:</b></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PJ Kelleher</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LifeSci Advisors</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Investors@cervomed.com</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">617-430-7579</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; margin: 0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>crvo20240930_424b3img001.jpg
<TEXT>
begin 644 crvo20240930_424b3img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !_ 9L# 2(  A$! Q$!_\0
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MHH **3.>AI: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@!*1ONFEI&Z4Q/8^>M49FU>]
M9_O&XD)_[Z-4GD2)=TC*@]2:O^/R^C>*KZV1"&E;SE8CC#<\?CG\JXJ29Y26
M=BQ/<UZT9IQ5CXZ6$E[1\_<]2\%:I!JL_P#8ZW*+<*"T6_(#CN![C^5=]%H6
MH6T@EAGB#KTY/^%?.$$\UM<1SV\C1S1L&1U."I'<5]!?#_QDOBG2C'<%5U&V
M $RCC>.S@>_?T->1B<!3YW574][ U(\JIO='11WMU",7MJP_Z:1?.OY=15^"
M>*XB$D+AT/<5+30 .@Q6<8M=;GIK0?115#4]4LM'L);W4+F.VMHAEI)&P/\
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M#^E0Z9IVGQQVL6XHK>0QY))Y+>IKWJBB,[*U@<;NYXK]M^-G_/G#_P!\6_\
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M*"3N?/WQ ^'WBK6?'&I:AI^E--:S,ACD$T8SA%'0MGJ*YO\ X53XW_Z ;_\
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1** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>logosm.jpg
<TEXT>
begin 644 logosm.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0!P17AI9@  34T *@    @ !@$Q  (
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M!/7:MM"RCL !V%?JM_P>!)'9^'O@!:PJL<4-SJ^Q%& JB*V  'H*E_X(#_\
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(4 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
